BEIJING, Nov. 20 Sinovac Biotech Ltd. (Amex: SVA),a leading provider of biopharmaceutical products in China, today filed a Form6-K with the U.S. Securities and Exchange Commission (''SEC'') related to theinadvertent disclosure of unaudited, draft financial results for the three andnine month periods ending September 30, 2007, which should not be relied upon.Financial results for the three and nine month periods ending September 30,2007 will be issued by the Company once finalized.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccinesinclude Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) andAnflu(TM) (influenza). Sinovac is currently developing human vaccines againstthe H5N1 strain of pandemic influenza, and Japanese encephalitis. Additionalinformation about Sinovac is available on its website, http://www.sinovac.com .To be added to our distribution list, please email: [email protected]
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that arenot historical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update anyforward-looking statement, except as required under applicable law.For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email: [email protected]
Investors/Media: Stephanie Carrington / Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email: [email protected] [email protected]
SOURCE Sinovac Biotech Ltd.